Therapies

Newer glucagon products provide additional options for the treatment of severe hypoglycemia.

We were asked to consult on a case involving a 68-year-old man with type 1 diabetes (T1D). He recently experienced a severe hypoglycemic event resulting in hospitalization. The patient currently lives independently with his wife of 40 years and has had T1D since the age of 12....

A recent exploratory analysis of the REWIND trial evaluated a potential additive benefit to using a once-weekly GLP-1 RA.

How do DPP-4 inhibitors and sulfonylureas compare to SGLT2is and GLP-1 agonists regarding renal outcomes?

Dual and triple therapy just got a little easier.

Insulin delivery method or blood glucose monitoring – which is more important?

This article is part of a live interview with Dr. Engel, Associate Vice President, Cardiometabolic and Women's Health, Merck Research Laboratories.

The study aimed to investigate whether testing HbA1c will improve cardiovascular disease risk assessment.

How many years can semaglutide add to your life?

Since DPP-4 plays a role in infection for some coronaviruses, there is increased interest in whether patients using DPP-4 inhibitors are at greater pneumonia risk.

CGM use in young children with type 1 diabetes has its benefits and challenges, according to their parents.